TY - JOUR
T1 - Repeated measures of extremely high levels of high-density lipoprotein cholesterol and subsequent all-cause mortality and cardiovascular events
T2 - A longitudinal study
AU - Kobayashi, D.
AU - Noto, Hiroshi
AU - Shimbo, Takuro
AU - Ino, T.
AU - Osugi, Yasuhiro
AU - Takahashi, O.
AU - Asai, Kanichi
PY - 2019/9
Y1 - 2019/9
N2 - Background and aims: Extremely high level high-density lipoprotein (HDL) cholesterol had been cautioned as risk factor for all-cause mortality and cardiovascular disease. However, both the physician and the patient may underestimate the risk due to the emphasis on “good cholesterol”, resulting in passive treatment or adoption of a less healthy lifestyle. The aim of this study is to re-evaluate the association with longitudinal data to account for fluctuations in HDL cholesterol and covariates. Methods: We conducted a retrospective longitudinal study at a large teaching hospital in Tokyo, Japan, from 2005 to 2016. We included all adults who participated in health check-ups. Outcomes were all-cause mortality and cardiovascular events. HDL cholesterol was repeatedly measured at each visit and categorized into five groups. The time-varying Cox model was applied to longitudinal analyses. Results: We included a total of 83,100 participants; the mean age was 45.5 (standard deviation:12.4) years; 41,013 (49.4%) were male, and 4475 participants belonged to the extremely high level HDL cholesterol group (>90 mg/dl). During a median follow-up of 1746 (interquartile range:740–3112.5) days, 382 (0.5%) participants died, and 2023 (2.4%) experienced cardiovascular events. Although the extremely high level HDL cholesterol group had significantly lower hazard ratios (HRs) for all-cause mortality (HR:0.49, 95%confidence interval(CI):0.26–0.90) and cardiovascular events (HR:0.71, 95%CI:0.54–0.94) compared to the low group (<40 mg/dl), HRs were higher than in the very high level HDL cholesterol group. Conclusions: Our study demonstrated that extremely high level HDL cholesterol has significantly lower risks of all-cause mortality and cardiovascular events compared to low level, but higher risks compared to very high level, as previously reported.
AB - Background and aims: Extremely high level high-density lipoprotein (HDL) cholesterol had been cautioned as risk factor for all-cause mortality and cardiovascular disease. However, both the physician and the patient may underestimate the risk due to the emphasis on “good cholesterol”, resulting in passive treatment or adoption of a less healthy lifestyle. The aim of this study is to re-evaluate the association with longitudinal data to account for fluctuations in HDL cholesterol and covariates. Methods: We conducted a retrospective longitudinal study at a large teaching hospital in Tokyo, Japan, from 2005 to 2016. We included all adults who participated in health check-ups. Outcomes were all-cause mortality and cardiovascular events. HDL cholesterol was repeatedly measured at each visit and categorized into five groups. The time-varying Cox model was applied to longitudinal analyses. Results: We included a total of 83,100 participants; the mean age was 45.5 (standard deviation:12.4) years; 41,013 (49.4%) were male, and 4475 participants belonged to the extremely high level HDL cholesterol group (>90 mg/dl). During a median follow-up of 1746 (interquartile range:740–3112.5) days, 382 (0.5%) participants died, and 2023 (2.4%) experienced cardiovascular events. Although the extremely high level HDL cholesterol group had significantly lower hazard ratios (HRs) for all-cause mortality (HR:0.49, 95%confidence interval(CI):0.26–0.90) and cardiovascular events (HR:0.71, 95%CI:0.54–0.94) compared to the low group (<40 mg/dl), HRs were higher than in the very high level HDL cholesterol group. Conclusions: Our study demonstrated that extremely high level HDL cholesterol has significantly lower risks of all-cause mortality and cardiovascular events compared to low level, but higher risks compared to very high level, as previously reported.
UR - http://www.scopus.com/inward/record.url?scp=85068477702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068477702&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2019.06.918
DO - 10.1016/j.atherosclerosis.2019.06.918
M3 - Article
C2 - 31295627
AN - SCOPUS:85068477702
VL - 288
SP - 17
EP - 25
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
ER -